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Abstract

•

Estrogen receptor-beta (ERβ) is a drug target for memory consolidation in postmenopausal women. Herein is reported a
series of potent and selective ERβ agonists (SERBAs) with in vivo efficacy that are A–C estrogens, lacking the B and D
estrogen rings. The most potent and selective A–C estrogen is selective for activating ER relative to seven other nuclear
hormone receptors, with a surprising 750-fold selectivity for the β over α isoform and with EC50s of 20–30 nM in cell-based
and direct binding assays. Comparison of potency in different assays suggests that the ER isoform selectivity is related to
the compound’s ability to drive the productive conformational change needed to activate transcription. The compound also
shows in vivo efficacy after microinfusion into the dorsal hippocampus and after intraperitoneal injection (0.5 mg/kg) or
oral gavage (0.5 mg/kg). This simple yet novel A–C estrogen is selective, brain penetrant, and facilitates memory
consolidation.

Introduction

ERβ agonists have a number of promising clinical applications.(1) Current ERβ agonist drug lead molecules
possess a phenolic ring, with varying substituted aromatic ring systems on the other half of the molecule,
typically comprising another phenolic or indole-like ring system (Figure 1a). One of these, WAY-200070
(benzoxazole), has shown efficacy as an anxiolytic/antidepressant and has 68-fold selectivity for ERβ over
ERα.(1−3) Some ERβ agonists have progressed into human clinical trials for different disease indications, ranging
from schizophrenia (Eli Lilly; NCT01874756) to fragile-X syndrome (Parc de Salut Mar; NCT01855971) to memory
loss and hot flashes (National Institutes on Aging; NCT01723917).(4) Studies presented herein focus on one of
the more promising new clinical applications of ERβ agonists for treating neuronal symptoms caused by estrogen
deficiency in menopause, as illustrated in animal model studies using diarylpropionitrile (DPN).(5)

Figure 1. Estrogen receptor agonist structures. (a) Previously reported ERβ agonists. Figure adapted from ref (35). (b)
Structure of ISP358-2, (c) estradiol (E2), and (d) ISP358-2 (red) overlaid on top of E2 to illustrate the similarity to the
naturally occurring estrogen.

17β-Estradiol (E2) is a critical modulator of hippocampal synaptic plasticity and hippocampal-dependent memory
formation in male and female rodents.(6) E2 levels decrease in both sexes as people age but drop much more
precipitously in women during the menopausal transition. ERβ is the predominant ER isoform in the
hippocampus and plays an important role in mediating estradiol’s effects on neural plasticity and
neuroprotection, which could be pivotal during aging and in Alzheimer’s disease (AD). For example,
overexpression of ERβ in a rat model of AD significantly reduced hippocampal AD pathology and improved
learning and memory.(7) Moreover, specific alleles of the gene for ERβ (Esr2), but not ERα, are associated with
decreased AD risk in men and women,(8) supporting ERβ as a putative drug target for AD.
APOE4 is the most well established genetic risk factor for Alzheimer’s disease (AD). Women with
the APOE4 genotype are 2–4 times more likely to develop AD than women without APOE4 or than men of any
other APOE genotype.(9−11) APOE4 carriers are also much more likely to show symptoms of anxiety and
depression.(12) A major contributor to these risks in women is menopausal estrogen loss, as estrogens are
neuroprotective for brain regions like the hippocampus and cortex that mediate cognitive function and
deteriorate in AD.(13) As such, drugs that facilitate estrogen-mediated effects on cognition, like the selective
ERβ agonists (SERBAs) being developed herein, may reverse memory loss and alleviate anxiety and depression in
aging females, but estrogen-based hormone replacement therapy is associated with increased risk of various
diseases (thought to be associated with ERα agonist activity), including breast cancer (especially lobular) as well
as stroke, gallbladder disease, and venous thromboembolism.(14−18)Accordingly, any ERβ agonist therapeutic
should be selective for ERβ over ERα agonist activity.
Recently, we reported a novel ERβ agonist that was more selective for ERβ versus ERα activation than previously
reported clinical candidates.(19) This ERβ agonist was in a unique structural class, comprising a phenol ring
tethered to a 4-hydroxymethyl-cycloheptane ring system. However, the presence of the 4-substituted
cycloheptane ring presents synthetic and stereochemistry challenges, making it less desirable as a drug lead.
Herein is reported the optimization and characterization of a related class of molecules, comprised of a 4hydroxymethyl-cyclohexane ring tethered to a phenol ring, making it an A–C estrogen that closely resembles the
naturally occurring estrogen molecule but lacks the B and D rings (Figure 1b–d). Whereas A–CD estrogens have
been widely studied and reported to have up to 15-fold selectivity for ERβ,(16−23) the simpler A–C estrogens
reported herein show even higher selectivity for ERβ over ERα. These A–C estrogens represent a surprisingly
simple yet novel class of isoform selective ERβ agonists, with potential for treating age-related memory decline
in postmenopausal women.

Results
Compound Synthesis
Commercially available 4-(4-hydroxyphenyl)cyclohexanone 1 was transformed into 2° or 3° alcohols 2 or 3 by
reaction with NaBH4 or excess methyl lithium, respectively, or into oxime 4 by condensation with hydroxylamine
(Scheme 1). The stereochemistries of 2 and 3 were assigned based on their NMR spectral data. In particular, for
2° alcohol 2, the alcohol methane proton appears as a triplet of triplets at δ 2.38 (J = 11.8, 3.4 Hz); the large
couplings are consistent with an axial–axial disposition of this proton, and thus the hydroxyl group is equatorial.
Signals at δ 69.5 and 31.1 ppm in the 13C NMR spectrum of 3, assigned to the 3° alcohol and methyl carbons, are
in good agreement with cis-1,4-alcohols of this type.(24) The t-butyldimethylsilyl ether 5underwent olefination
with the ylide generated from methyltriphenylphosphonium bromide to give 6. Cleavage of the silyl ether using
TBAF gave 7; catalytic hydrogenation of 7 gave 8 as a mixture of stereoisomers. Reaction of 7 with excess
paraformaldehyde, MgCl2, and NEt3 gave the substituted salicaldehyde 9, which upon reaction with
hydroxylamine afforded the oxime 10. Dihydroxylation of 6, followed by cleavage of the silyl ether, gave 12 as a
single stereoisomer after chromatographic purification. The stereochemistry of 12 was assigned as indicated

based on the known stereochemistry of osmium-catalyzed dihydroxylation of 4-tbutylmethylenecyclohexane.(25) Hydroboration-oxidation of 6 using BH3–THF produced an inseparable mixture
of stereoisomeric primary alcohols cis-13 and trans-14 in a 2:1 ratio as determined by integration of the 1H NMR
signals for the hydroxymethylene protons for each (δ 3.60 and 3.39 ppm, respectively). The stereochemistry of
the isomers was tentatively assigned on the basis of the relative chemical shift of these two signals; the signal
for an axial hydroxymethylene (i.e., cis-isomer) appears downfield compared to that for an equatorial
hydroxymethylene.(24) Alternatively, hydroboration-oxidation using 9-BBN afforded a mixture in which trans14 was in greater proportion compared to cis-13 (2:3, cis:trans). The use of these two borane reagents to tune
the cis:trans outcome for 4-substituted methylenecyclohexanes has previously been reported.(26,27)Cleavage
of the silyl ether using TBAF gave a mixture of stereoisomeric 4-(4-hydroxymethylcyclohexyl)phenols cis15/trans-16. Treatment of a mixture of the stereoisomers 15/16 (2:3, cis:trans) with DDQ (0.5 equiv) led to a
separable mixture of a bicyclic ether 17 and trans-16. The tentative structural assignment for trans-16 was
corroborated by single-crystal X-ray diffraction analysis (Figure 7a).(28) Isolation of the unreacted trans-16 is
rationalized on the basis of the faster rate of oxidation of cis-15. Because oxidation of either cis- or trans-4-(4hydroxymethylcyclohexyl)phenol proceeds via the same benzylic carbocation intermediate (i.e., 18, Scheme 2),
the activation energy for the formation of this intermediate will be lower for the less stable cis-15 in comparison
to trans-16, and thus oxidative cyclization of the cis-isomer will be faster. Reaction of 17 with MgCl2 and
trimethylamine led to an intramolecular elimination reaction to afford the cyclohexene (±)-19 (Scheme 1). The
structure of 19 was assigned on the basis of its NMR spectral data; in particular, the signal for the olefinic proton
appears as a narrow multiplet at ca. δ 5.95 ppm. This signal is characteristic of other 1-(4hydroxyphenyl)cyclohexenes.(29)

Scheme 1. a aReagents: (a) NaBH4/MeOH (90%); (b) MeLi/Et2O (37%); (c) H2NOH-HCl, Amberlyst, ethanol (70%); (d) TBSCl,
imidazole (83%); (e) Ph3PCH3+ Br–, n-BuLi (84%); (f) TBAF/THF (73–78%); (g) H2, Pd/C, (h) paraformaldehyde, MgCl2,
NEt3 (40%); (i) H2NOH–HCl, NaHCO3, ethanol (69%); (j) cat. OsO4, NMO (1.4 equiv) (86%); (k) BH3-THF, then 30% H2O2/1N
NaOH; (l) 9-BBN, then 30% H2O2/1N NaOH; (m) DDQ (0.5 equiv)/CH2Cl2 (16, 47%; 17, 37%); (n) MgCl2, NEt3 (78%).

Scheme 2. Oxidation of the cis- or trans-4-(4-Hydroxymethylcyclohexyl)phenol via the Same Benzylic Carbocation
Intermediate

Silyl ether 20 (prepared from 1) underwent Horner–Emmons olefination with triethyl phosphonoacetate to afford the
unsaturated ester (±)-21; desilylation with TBAF gave the phenol (±)-22 (Scheme 3). Reduction of 21 with DIBAL,
followed by deprotection of the silyl ether, yielded the allylic alcohol (±)-24. Catalytic hydrogenation of 24 gave a
separable mixture of alcohol 25 and the over-reduced ethyl cyclohexane derivative 26.

Scheme 3. aaReagents: (a) TBDPSCl, imidazole (93%); (b) EtO2CCH2P(O)(OEt)2, NaH (95%); (c) DIBAL, CH2Cl2, −40 °C (quant);
(d) TBAF (80%); (e) H2 (30 psi), 20% Pd/C (25, 14%; 26, 60%).

TR-FRET and Cell-Based Transcriptional Assays

Initial screening of compounds was performed in a TR-FRET displacement assay, which detects binding to the ERβ LBD
(see Figure 2 for dose–response curves for selected compounds and Supporting Information, Figure S1, for dose–
response curves for all compounds). In this assay, EC50s were measured for all compounds that were synthesized, with

EC50 values summarized in Table 1. The most potent compounds were 16 (hereafter referred to as ISP358-2)
(hydroxymethyl substitution), 25 (hydroxyethyl substitution), and 8 (methyl substitution), which all had EC50s < 30 nM
for ERβ. ISP358-2 is the pure trans isomer and was found to bind with higher affinity to ERβ than the mixture of cisand trans-stereoisomers (15/16). While having a methylene (ISP358-2) or ethylene (25) linker to the hydroxyl group
leads to potency, the direct substitution of the hydroxyl on the cyclohexane ring yields a significant decrease in
affinity (EC50 of 7,520 nM for 2). While introduction of unsaturation into the alkyl linker (24) also led to a decrease in
affinity (680 nM), introduction of unsaturation into the cyclohexane ring (18) only decreased affinity modestly (49
nM). ISP358-2 was also tested for binding to ERα and bound with only 12-fold higher affinity to ERβ (EC50 of 24
nM; Figure 2b) in this TR-FRET assay, which measures direct binding to the isolated LBD.

Figure 2. Estrogen receptor binding assays. (a) TR-FRET binding assay for binding to the ligand binding domain (LBD) of ERβ.
(b) ISP358-2 binding to the LBDs of ERβ and ERα. ISP358-2 has modest 12-fold selectivity for ERβ (EC50 = 24 ± 5 nM) relative
to ERα (EC50 = 289 ± 92 nM) in this assay.

Table 1. Estrogen Receptor Assay Dataa

a

Reported values are EC50s, with values in nM. *Average of two data sets with EC50s of 31 ± 7 nM (Figure 5a) and 23 ± 8 nM
(Supporting Information, Figure S2), so selectivity ranges from 658 to 886 with an average of 750.

ISP358-2 was further screened in a nuclear hormone receptor functional assay (Figure 3), where transcriptional
activation was measured due to binding and activation of a chimeric receptor comprised of the LBD of a hormone

receptor of interest (e.g., ERβ) tethered to the DNA binding domain (DBD) of GAL4. This assay was done to assess
selectivity for activating estrogen receptor versus other nuclear hormone receptors. No significant agonist activity
was observed for compound ISP358-2 for any of the nuclear hormone receptors tested (except for the estrogen
receptor) at concentrations ranging from 0.25 to 25 μM (Figure 3a). Thus, ISP358-2 is not an agonist for the following
receptors: androgen receptor (AR), glucocorticoid receptor (GR), mineralocorticoid receptor (MR), peroxisome
proliferator-activated receptor (PPARδ), progesterone receptor (PR), thyroid hormone receptor (TRβ), and vitamin D
receptor (VDR) (see Supporting Information, Table S1, for control compound EC50s for each nuclear hormone tested).
In a follow-up 10-point titration in this same assay, ISP358-2 was found to be 2.6-fold selective for binding and
activating the full-length chimeric ERβ (357 ± 26 nM) relative to full-length chimeric ERα (930 ± 69 nM). This assay
(Figure 3) measures activation of transcription rather than simply binding of agonist to the ER LBD (as in Figure 2), but
it uses an unnatural chimeric protein (ER LBD fused to a GAL4 DBD) that may not accurately reflect the actual agonistinduced activation that occurs under native conditions.

Figure 3. Nuclear hormone receptor specificity assay for ISP358-2. (a) Agonist activity was measured in the GeneBLAzer cellbased transcriptional activation assay at three concentrations of ISP358-2, using chimeric nuclear hormone receptors (NRs)
comprised of the relevant NR ligand binding domains (LBDs) and the DNA binding domain (DBD) from GAL4. Assay was with
nine different NRs: androgen receptor (AR), glucocorticoid receptor (GR), mineralocorticoid receptor (MR), peroxisome
proliferator-activated receptor (PPARδ), progesterone receptor (PR), thyroid hormone receptor (TRβ), and vitamin D
receptor (VDR). ISP358-2 has high selectivity for binding to ER relative to other nuclear receptors (NRs). (b) Agonist activity
dose–response curve (open symbols) in the GeneBLAzer assay for ERβ and ERα, showing a modest 2.6-fold selectivity for
ERβ (EC50 = 357 ± 26 nM) over ERα (EC50 = 930 ± 69 nM). Data from (a) are included for comparison (closed symbols).

When the coactivator form of the TR-FRET LBD binding assay was performed (Figure 4a), the ISP358-2 compound
(Figure 4b) was found to be 15-fold selective (Figure 4c) for binding to ER and recruiting the PPARγ coactivator
peptide to ERβ (191 ± 15 nM) relative to ERα (2,940 ± 390 nM). This assay measures activation of the ER LBD, in that it
measures binding and agonist-induced recruitment of the coactivator peptide rather than simply binding of agonist to
the receptor.

Figure 4. Specificity assay for ISP358-2 binding in a coactivator assay. (a) This assay measures recruitment of a labeled
coactivator peptide to the ERα or ERβ LBD, induced by the binding of an ER agonist (ISP358-2, in this case). The coactivator
peptide is derived from the PPARγ coactivator protein 1a. Figure is adapted from the ThermoFisher manual. (b) Chemical
structure of ISP358-2. (c) ISP358-2 dose–response curve in the coactivator assay, giving an IC50 of 191 ± 15 nM for ERβ and
2,940 ± 390 nM for ERα, giving an ERβ selectivity of 15-fold.

Finally, a cell-based transcriptional activation assay, which employs a full length and native ER (comprised of an ER
LBD and an ER DBD), was performed. Unlike the previous assays, this assay is cell-based, so it best mimics the in vivo
situation. The most potent and selective compound tested in this assay is ISP358-2, which has an ERβ agonist potency
of 31 ± 7 nM (Figure 5a and Supporting Information, Figure S2a; the assay was performed in duplicate, with values of
31 nM and 23 nM obtained, for an average of 27 nM) and an ERα agonist potency of 20,400 ± 859 nM (Figure 5b).
This makes the ERβ/ERα selectivity ratio ∼750 in this more physiologically relevant assay. ISP358-2 showed no
antagonist activity for ERβ (Figure 5c) or ERα (Figure 5d) at concentrations up to 10 μM.

Figure 5. Specificity assay for ISP358-2 in cell-based assays. (a) ERβ and (b) ERα agonist activity, based on activation of
transcription by a full length estrogen receptor. (c) ERβ and (d) ERα antagonist activity, based on inhibition of estradiolinduced transcription by an antagonist compound. Average ERβ agonist potency is 27 ± 4 nM (data here has EC50 of 31 ± 7)
in (a), and ERα agonist potency is 20,400 ± 860 nM. This gives an ERβ selectivity of ∼750-fold. No measurable antagonist
activity was observed for ERβ or ERα at concentrations of ISP358-2 up to 10 μM in (c) and (d).

In Vitro Druggability: CYP450 Binding, hERG and Nephelometry

ISP358-2 shows no inhibition of CYP1A2 and CYP2D6, and only weak inhibition of CYP2C9 (EC50 = 34 ± 4.7 μM) and
CYP3A4 (EC50 = 89 ± 18 μM) (Figure 6). ISP358-2 does not bind to hERG, showing only 14% activity at 100 μM, and
nephelometry (done for ISP171, 15/16, the mixture of isomers) shows no significant aggregation, indicating good
solubility at concentrations up to 300 μM (Supporting Information, Figure S3).

Figure 6. Cytochrome P450 inhibition by ISP358-2. Inhibition of CYP450 activity (Promega P450-Glo assay) by ISP358-2 for:
CYP2D6 and CYP3A4 (EC50 = 89 ± 18 μM), CYP1A2, and CYP2C9 (EC50 = 34 ± 4.7 μM).

Docking Studies
ISP358-2 (Figure 7a) was docked into the binding site of agonist-conformation ERα in two conformations with similar
docking energy. In one binding mode (Figure 6d,e), the phenolic hydroxyl interacts with the Arg394/Glu353 (energy =
−7.6 kcal/mol), and in another mode the ISP358-2 molecule is flipped 180° (energy = −7.8 kcal/mol) with the aliphatic
hydroxyl interacting with Arg394/Glu353. ISP358-2 binds in the agonist-conformation ERβ pocket (Figure 7f,g) with
the phenolic hydroxyl interacting with the Arg394/Glu353 in the lowest energy docking pose (energy = −8.0 kcal/mol).
In both cases, there are significant hydrophobic interactions between binding site residues and the bound ISP358-2,
although the ERβ pocket is smaller and makes for a tighter fit. In both cases, the hydroxymethyl group is proximal
enough (3.0 Å) to the His524 to participate in the hydrogen bonding interaction that is typically seen for ER agonists,
although in ERβ the hydrogen bond to the aliphatic alcohol may be with the backbone carbonyl of Gly472. In ERβ,
there are more hydrophobic interactions that constrain the hydroxymethyl-cyclohexyl ring (ring C) to be nearly planar
with the phenolic ring (ring A) (Figure 7c), as it is in the native estrogen molecule. This is in contrast to the binding
pose in ERα, where the two rings are nearly orthogonal (Figure 7b). The ERβ hydrophobic interactions are with
Phe356, Met340, Phe355, and Leu298, near the phenol ring, and with Leu476 and Ile373 near the hydroxymethyl
group and with Ala302 and Leu298 near the cyclohexane ring (Figure 7f,g). A control docking study of E2 reproduced
the expected binding orientation based on the crystal structure (Supporting Information, Figure S4).

Figure 7. Structural analysis of ISP358-2. (a) Crystal structure (Ortep rendering) of ISP358-2, showing
the trans stereochemistry of the cyclohexane ring. (b,d,e) Docked structure of ISP358-2 in the ERα binding pocket, showing:
(b) binding orientation relative to estradiol (green) and (d,e) interactions with active site residues, including hydrogen
bonding with Arg394, Glu353, and His524. (c,f,g) Same as (b), (d), and (e) but for ISP358-2 bound to ERβ. Hydrophobic
interactions in ERβ are observed between the phenol ring of ISP358-2 and Phe356, Phe355, and Met340 and between the
cyclohexane ring and Leu476, Ala302, Ile373, and Leu298. The phenol rings are colored white, and the hydroxymethylcyclohexane ring is cyan (in ERα, (e)) or green (in ERβ, (g)). Docking energy is −7.6 kcal/mol in ERα and −8.0 kcal/mol in ERβ.

2D ligand plots (d,f) were created using PoseView.(37) The ERα receptor for agonist (pdb 1ere)(36) and antagonist
(pdb 1err)(48) conformations and the ERβ receptor for agonist (pdb 2jj3)(49)and antagonist (pdb 1l2j)(50) conformations
were used for docking calculations.

Assessment of Memory Consolidation

As described in detail in the Experimental Section, memory consolidation was assessed in all studies using acute
treatments administered immediately after training. That is, for each task, mice completed a single training trial and
then were immediately treated with control vehicle or experimental compounds. Memory consolidation was
measured 24 or 48 h later. Briefly, in the object recognition task, mice explored two identical objects during training,
immediately after which they were treated with the compounds described below. Memory for the training objects
was tested 48 h later by allowing mice to explore one training object and one novel object. In the object placement
task, mice again explored two identical objects and received immediate post-training treatments. Memory was tested
24 h later by allowing mice to explore a training object in its original location and a training object in a new location.
More time than chance, or than the control group, spent with the novel or moved object indicated intact
consolidation of memory for the training objects. Each mouse completed both tasks, the order of which was
counterbalanced within each group. Two weeks separated bouts of testing to allow any acute effects of the drugs to
dissipate before the next treatment.

Dorsal Hippocampal Infusion

We first investigated the effects of direct intrahippocampal infusion of ISP358-2 on object recognition and spatial
memory consolidation in ovariectomized mice (Figure 8a). Five groups of mice were tested (Figure 8b,c): vehicle
(negative control), DPN (positive control), and three doses of ISP358-2 (10 pg/hemisphere, 100 pg/hemisphere, and 1
ng/hemisphere). For object placement (Figure 8b), one-sample t-tests indicated that mice receiving vehicle or 10 pg
of ISP358-2 did not spend significantly more time than chance with the moved object (ts(7) = 0.44 and 1.19,
respectively, p > 0.05; n = 8), indicating that these groups did not exhibit a memory for the training object location. In
contrast, mice receiving DPN, 100 pg of ISP358-2, or 1 ng of ISP358-2 spent significantly more time than chance with
the moved object (ts(6) = 4.5, 10.3, and 3.4, respectively, p < 0.05; n = 7), indicating robust memories for the training
object location. In addition, a one-way ANOVA conducted on the time spent with the moved object indicated a
significant main effect of treatment (F(4,32) = 2.97, p = 0.034). Fisher’s LSD posthoc tests indicated that the DPN, 100 pg,
and 1 ng groups spent significantly more time with the moved object than the vehicle group, whereas the vehicle and
10 pg groups did not differ from each other. Together, these data suggest that dorsal hippocampal infusion of 100 pg
or 1 ng of ISP358-2 enhanced object placement memory consolidation.

Figure 8. Behavioral assays. (a) Overview of the OR and OP testing procedures. When infused into the DH, DPN at the 100
pg and 1 ng/hemisphere doses of ISP358-2 significantly increased the time that was spent with the moved (b) or novel (c)
object relative to chance (15 s; *p < 0.05; **p < 0.01) and vehicle (#p < 0.05; ##p < 0.01), suggesting that ISP358-2 enhanced
memory consolidation to a similar extent as the positive control DPN. When injected IP, DPN and 0.5 mg/kg ISP358-2
enhanced memory consolidation in the OP (d) and OR (e) tests (###p < 0.001). Five mg/kg ISP358-2 also enhanced OP
memory consolidation. Similarly, oral gavage treatments of 0.5 and 5 mg/kg ISP358-2 enhanced memory consolidation in
the OP (f) and OR (g) tests. (a) Adapted from ref (38).

Results for object recognition (Figure 8c) were nearly identical. Neither the vehicle nor 10 pg of ISP358-2 groups
showed a preference for the novel object (ts(9–10) = 1.08 and 0.88, respectively, p > 0.05; n = 10–11). However, the DPN,
100 pg of ISP358-2, and 1 ng of ISP358-2 groups all spent significantly more time than chance with the novel object
(ts(9–10) = 2.35, 3.16, and 1.08, respectively, p < 0.05; n = 10–11). Moreover, the main effect of treatment was
significant (F(4,48) = 3.69, p = 0.011), and posthoc tests confirmed that the DPN, 100 pg of ISP358-2, and 1 ng of ISP3582 groups, but not the 10 pg of ISP358-2 group, differed significantly from vehicle. As with object placement, these
data indicate that dorsal hippocampal infusion of 100 pg or 1 ng of ISP358-2, but not 10 pg of ISP358-2, enhanced
object recognition memory consolidation.

Intraperitoneal Injection

We next used a new set of mice to investigate whether systemic administration of ISP358-2 also provide similar
memory enhancing effects as intrahippocampal infusion (Figure 8d,e). Intraperitoneal (IP) injection is a common,
reliable, and convenient systemic treatment in which the injected drug is absorbed into the blood vessels through the
peritoneum.(30) Because the doses of the drugs for intrahippocampal infusion are much smaller than that needed to
cross the blood–brain barrier, we examined a range of IP doses based on the cell-based assay and DH infusion results
above and previous work showing that IP injections of 0.05 mg/kg DPN enhanced object recognition memory.(31) In
our cell-based assays, the EC50 of ISP358-2 was approximately 10 times higher than that of DPN. Moreover, our
behavioral tests showed that ISP358-2 enhances hippocampal memory at a concentration 10 times higher than DPN.
Therefore, our IP doses of ISP358-2 were at least 10 times higher than DPN (0.5 and 5 mg/kg). We thus tested four
groups of mice as follows: vehicle (negative control), DPN (positive control), and two doses of ISP358-2 (0.5 and 5
mg/kg).
For object placement (Figure 8d), one-sample t-tests indicated that mice receiving vehicle did not show a preference
for the moved object (t(8) = 0.68, p > 0.05; n = 9). However, the DPN, 0.5 mg/kg ISP358-2, and 5 mg/kg ISP358-2 groups
all spent significantly more time than chance with the moved object (ts(9–11) = 3.20, 3.93, and 2.78, respectively, p <
0.05; n = 10–12), suggesting that systemic administration of ISP358-2 enhanced object placement memory
consolidation. Moreover, the main effect of treatment was significant (F(3,38) = 3.63, p = 0.021), and posthoc tests
showed that the 0.5 mg/kg ISP358-2 group differed significantly from vehicle. These data demonstrate that IP
injection of ISP358-2 enhances spatial memory consolidation in a manner similar to dorsal hippocampal infusion.
Similar results were observed for object recognition (Figure 8e). One-sample t-test results showed that mice receiving
vehicle did not spend significantly more time than chance with the novel object (t(9) = 1.40, p > 0.05; n = 10). In
contrast, the DPN and 0.5 mg/kg ISP358-2 groups exhibited a significant preference for the novel object relative to
chance (ts(8 and11) = 3.52 and 4.17, respectively, p < 0.01; n = 9 and 12). There was also somewhat of a trend for the 5
mg/kg ISP358-2 to prefer the novel object (t(12) = 1.65, p = 0.125; n = 13). In addition, the main effect of treatment was
significant (F(3,40) = 5.05, p = 0.005), and posthoc tests verified that the DPN, 0.5 mg/kg ISP358-2, and 5 mg/kg ISP358-2
groups differed significantly from the vehicle group. Together, the object placement and object recognition data
suggest that IP administration of ISP358-2, particularly the 0.5 mg/kg dose, enhances object recognition and spatial
memory consolidation similar to dorsal hippocampal infusion. Importantly, these data also demonstrate brain
penetrance and behavioral efficacy in ovariectomized mice.

Oral Gavage

Given the mnemonic effectiveness of IP injection, we next assessed whether oral administration of ISP358-2 could
enhance memory consolidation (Figure 8f,g). Oral gavage is a common procedure in scientific experiments delivering
the drug directly into the stomach by means of a syringe.(32)Although it is highly effective and more accurate than
other oral administration methods such as administration through delivery in food and/or water, it is more invasive
and stressful.(33) Because we observed that IP injection of ISP358-2 enhanced hippocampal memory consolidation,
we used the same doses for oral gavage as for IP injections (vehicle, 0.5 or 5 mg/kg ISP358-2, and 0.05 mg/kg DPN).
Similar results were observed for oral administration as were observed for IP injection ISP358-2. For object placement
(Figure 8f), one-sample t-test results showed that mice receiving vehicle did not spend significantly more time than
chance with the moved object (t(8) = 0.54, p > 0.05; n = 9). However, the DPN, 0.5 mg/kg ISP358-2, and 5 mg/kg
ISP358-2 groups all exhibited a significant preference for the moved object relative to chance (ts(8–9) = 2.76, 3.65, 5.06,
respectively, p < 0.05; n = 9–10), suggesting that oral administration of ISP358-2 enhanced spatial memory
consolidation. Also, one-way ANOVA showed that the main effect of treatment was significant (F(3,33) = 5.04, p =
0.006), and posthoc tests verified that the DPN, 0.5 mg/kg ISP358-2, and 5 mg/kg ISP358-2 groups differed
significantly from the vehicle group. Likewise, for object recognition (Figure 8g), one-sample t-tests indicated that
mice receiving vehicle did not show a preference for the novel object (t(8) = 0.25, p > 0.05; n = 9). In contrast, the DPN,
0.5 mg/kg ISP358-2, and 5 mg/kg ISP358-2 groups all spent significantly more time with the novel object relative to
chance (ts(7–9) = 3.89, 5.37, and 2.36, respectively, p < 0.05; n = 8–10). Moreover, the main effect of treatment was
significant (F(3,32) = 3.02, p = 0.044), and posthoc tests showed that the DPN, 0.5 mg/kg ISP358-2, and 5 mg/kg ISP358-2
groups differed significantly from vehicle. Together, the object placement and object recognition behavior results

demonstrate that oral administration of ISP358-2 enhances object recognition and spatial memory consolidation
similar to dorsal hippocampal infusion and IP injection. These data also suggest the oral bioavailability of ISP358-2 in
ovariectomized mice.
Finally, we collected preliminary data to assess the effectiveness of orally gavaged ISP358-2 on spatial memory
consolidation in mice who experienced long-term estrogen deprivation. Mice that received ip injections of vehicle,
DPN, or ISP358-2 above remained in our colony for 4 months after ovariectomy. They were then trained in the object
placement task (using new objects) and then immediately given vehicle, DPN, or ISP358-2 via oral gavage in the same
doses described above (n = 9–12/group). Unlike mice gavaged within 1 month of ovariectomy (Figure 8f), DPN or
ISP358-2 did not enhance spatial memory consolidation in mice treated within 4 months of ovariectomy (Supporting
Information, Figure S5a). We then measured ERα and ERβ levels in the DH using Western blotting as per our previous
work(34) (ERα, 1:200, Santa Cruz Biotechnology; ERβ, 1:200, Santa Cruz Biotechnology); tissue was collected
approximately 2 and 5 months after ovariectomy. Levels of ERβ were significantly reduced 5 months after
ovariectomy relative to 2 months after ovariectomy (Supporting Information, Figure S5b; t9 = 2.46, p < 0.05). In
contrast, levels of ERα did not change (Supporting Information, Figure S5c). These data suggest that DPN or ISP358-2
did not enhance memory after long-term ovariectomy because of the reduced levels of ERβ. By extension, these data
also support in vivo selectivity of ISP358-2 for ERβ because, if ISP358-2 enhanced memory via binding to ERα, then it
should have been able to enhance memory consolidation after long-term ovariectomy because ERα levels were not
reduced. However, the fact that ERβ levels were reduced at a time at which ISP358-2 did not enhance memory
supports our hypothesis that it regulates memory via ERβ and not ERα.

Assessment of Peripheral Pathology or Cell Proliferation Due to ISP358-2 Treatment

In general, all the tissues from the 20 different specimens appeared similar. Heart: the cardiac tissues were all
unremarkable. The ventricular walls were intact and normal thickness. The atrial walls were intact with normal
thickness. There was no evidence of congenital defects such as myofiber disarray or ischemic heart disease or
ischemic injury. There was no evidence of inflammation or myocarditis. Kidney: The kidneys were all unremarkable.
The glomeruli were intact. The tubules appeared normal. There was no evidence of inflammation involving any of the
structures of the kidneys. Liver: The general architecture of the liver was intact and normal appearing with large
portal-types veins running together with hepatic ducts and hepatic arteries. The central veins were present and
normal appearing. A generalized appearance of low grade/mild ischemic injury was present in all samples. This
seemed nonspecific, was appreciated in all specimens, and could be secondary to early ischemic damage or autolysis
that occurred post mortem. In several animals, small foci of cellular necrosis were observed likely secondary to
ischemia. Two animals showed areas with mild, low grade inflammation that was small and focal. One animal (R15-IP24V) had multifocal areas of an organized inflammatory infiltrate composed primarily of mononuclear lymphocytes.
Overall, there was no evidence of acute inflammation composed of neutrophils or damage to structures in the liver,
such as hepatic ducts. Bloodwork chemistry and hematology data (Supporting Information, Figure S7) for treated
animals did not show significant deviations from expected reference ranges, relative to vehicle, except for modest
effects due to hemolysis that was likely due to sample collection via cardia puncture. Finally, while E2 caused
statistically significant proliferation of MCF-7 breast cancer cells at doses of 10, 100, and 1000 nM neither ISP358-2
nor DPN showed any significant proliferation relative to untreated control cells (Figure S8).

Discussion
ERβ has previously been pursued as a drug target for a wide range of conditions, including anxiety, depression,
schizophrenia, and Alzheimer’s disease, with representative ERβ drug lead agonist compounds shown
in Figure 1a.(35) Compounds presented herein (Table 1) differ from these previously reported compounds in that they
are more selective for ERβ over ERα (∼750-fold) and in that they are A–C estrogens that resemble the native 17βestradiol molecule, lacking only the B and D rings.

Structure–Activity Relationship for the A–C Estrogens
The binding affinity of 4-(4-substituted cyclohexyl)phenols were assessed in a TR-FRET ERβ binding assay
(Table 1 and Figure 2). In particular, compounds bearing a hydroxymethyl functionality attached to the cyclohexyl
core showed higher affinities, in the range 20–200 nM. Of the two components in the 2:1 mixture of cis- and trans-

stereoisomers 15/16 (EC50 = 180 nM), the trans-isomer was found to be more potent (ISP358-2, EC50 = 24 nM) than the
mixture. Introduction of unsaturation within the six-membered ring (18, EC50 = 49 nM) did not greatly reduce the
binding affinity compared to ISP358-2; however, conformational restriction, such as is present in the exocyclic allylic
alcohol, reduced affinity (24, EC50 = 680 nM). The presence of a third hydroxyl group led to greatly reduced binding
affinity (12, EC50 = 2700 nM). Finally, varying the distance between the phenolic OH and the aliphatic alcohol group
gave a larger range of binding affinities (2, EC50 = 7,520 nM; 25, EC50 = 11 nM). Those analogues having EC50 values
<200 nM were further tested in a cell-based transcriptional activation assay to evaluate their ERβ selectivity both in
terms of binding affinity and of efficacy in activating transcription in a biologically relevant system. The transstereoisomer ISP358-2, 8, 18, and 25 exhibited similar ERβ agonist potencies (EC50 ∼ 30–75 nM) in the TR-FRET assay,
but ISP358-2 stands out as being the most potent and selective in this more biologically relevant cell-based functional
assay. Interestingly, the hydroxyethyl analogue was less potent in the cell-based functional assay (25, EC50 = 75 vs 11
nM).
The potency differences observed in the assays may be due to the nature of what the assays measure. The TR-FRET
assay in Figure 2 measures only displacement of a fluorescently labeled estradiol ligand from the ligand binding
domain (LBD), which reflects binding affinity for the ligand that competitively displaces the fluorescent probe. In
contrast, the cell-based assay is more complicated and measures the entire sequence of molecular events leading to
transcriptional activation. This sequence of events involves a series of conformational changes (e.g., a rotation of
helix-12 of the ligand binding domain) that are triggered by the initial hormone binding.(36) The protein
conformational change in the estrogen receptor induced by agonist binding results in recruitment of a coactivator
protein and also triggers protein dimerization, ultimately resulting in DNA binding and transcriptional activation.
Additional interactions between the aliphatic hydroxyl group and the His475 residue of ERβ plays a role in the
conformational change involving nearby helix-12, which would be reflected in EC50 values in the cell-based functional
assay (Figure 5) but not in the TR-FRET binding assay (Figure 2).
All compounds tested showed no significant ERβ or ERα antagonist activity (EC50 > 10000 nM), thus also
demonstrating their selectivity as agonist vs antagonist activity (Table 1 and Figure 5c,d). Of the ERβ agonists, ISP3582 was the most selective, with ∼750-fold agonist selectivity for ERβ over ERα in the cell-based functional assay, but it
had only modest selectivity in the TR-FRET binding assay (Figure 2b).

Assay Differences Suggest Mechanism for Isoform Selectivity

As mentioned above, the cell-based assay for ISP358-2 indicates that it is ∼750-fold selective for ERβ agonist activity
over ERα agonist activity (Figure 5a,b), whereas the TR-FRET binding assay shows more modest 12-fold selectivity for
ERβ (Figure 2b). This could be because the TR-FRET binding assay simply measures binding affinity (to an isolated
LBD), whereas the cell-based assay measures transcription that is induced by agonist binding to a full-length and
native ERβ, which causes a productive conformational change in ERβ that includes rotation of helix-12 (leading to
recruitment of coactivators, dimerization, DNA binding, and then transcriptional activation). To test the hypothesis
that assay differences are due to these downstream activation events, two other assays were performed. In a first
assay, transcriptional activation was measured in a different cell-based assay, now using an unnatural chimeric
receptor (ER LBD fused to a GLA4 DBD). In this assay (Figure 3b), there was a modest 2.6-fold selectivity for ERβ. In a
second assay, ability of agonist binding to recruit binding of a coactivator peptide to the ER LBD was measured
(Figure 4a). In this assay, 15-fold selectivity for ERβ was observed (Figure 4c). Thus, ERβ versus ERα selectivity for
ISP358-2 varies significantly based on how well the assay incorporates native downstream activation events that
occur subsequent to binding to the ERβ binding pocket as a result of hormone-induced conformational changes. It
therefore appears that the significant ERβ versus ERα selectivity shown by ISP358-2 is not just a function of binding
affinity for the ERβ receptor (as measured in the TR-FRET assay in Figure 2b) but rather is a function of the ability to
induce the productive conformational change that leads to downstream activation of transcription (Figure 5a).
Consistent with the above hypothesis that ISP358-2 potency and selectivity are related to its ability to drive a
productive conformational change, docking studies show that ISP358-2 docks into the ERβ active site in a
conformation that differs significantly from that for the ERα binding site. Key differences occur where the estrogen C
ring is normally located (Figure 7c,f,g), thereby affecting positioning of the aliphatic hydroxyl group that interacts with
the His524 and/or Gly472 (backbone carbonyl) residues (Figure 7f,g) in the region known to be important for driving
the helix-12 conformational change that permits binding of coactivator. The ERβ hydrophobic interactions include π–

π stacking between Phe356 and the ISP358-2 phenol ring, along with Ala302, Leu298, Leu476, and Ile373 that
constrain the cyclohexyl ring and its attached hydroxymethyl methyl group in the “C ring” region (Figure 1d). These
unique hydrophobic interactions in the ERβ active site may be what drives the 90° rotation of the C (cyclohexane) ring
of ISP358-2 relative to the phenol ring in the ERβ pocket relative to the ERα pocket (Figure 7b,c), and in this way, they
could affect the adjacent coactivator pocket. This region of the 17β-estradiol binding pocket is known to affect the
accessibility and structure of the coactivator binding pocket and so could be the reason for the large differences in
agonist activity that were observed for ISP358-2. Future structural characterization studies are being planned to
address this question.

Druggability and Preliminary Safety Toxicity
While ISP358-2 binds to ER and activates transcription, it shows no significant off-target activity with seven other
nuclear hormone receptors (Figure 3a). ISP358-2 also showed no significant activity against the heart potassium ion
channel hERG (Supporting Information, Figure S3b) and no significant inhibition of the major drug metabolizing
cytochrome P450 enzymes, CYP2D6, CYP3A4, CYP2C9, and CYP1A2 (Figure 6). ISP358-2 was also reasonably soluble,
showing no aggregation in nephelometry assays (Supporting Information, Figure S3a).
To assess the potential of ISP358-2 to stimulate breast cancer cell growth, MTT assays with MCF-7 human breast
cancer cells were performed (Supporting Information, Figure S8). No significant changes in the growth of MCF-7 cells
were observed following treatment at any concentration of the ERβ agonists ISP358-2 or DPN compared to untreated
controls (Supporting Information, Figure S8b,c). However, the proliferation of MCF-7 cells treated with 1, 0.1, or 0.01
μM E2 was significantly increased (n = 3; p < 0.02, 0.05, 0.003, respectively) compared to untreated controls
(Supporting Information, Figure S8a). Furthermore, cell proliferation was significantly lower (n = 3; p ≤ 0.04 for both
compounds) in comparison to positive control MCF-7 cells treated with 0.01 μM E2.
To assess potential peripheral pathology due to ISP358-2 treatment, a histological analysis of tissue slices of treated
animals was performed (Supporting Information, Figure S6). Overall, tissue changes due to treatment were
unremarkable. Mild, global ischemic changes were noted in the livers of all animals. It is difficult to assign a specific
pattern or significance to this finding. These changes likely represent hypoperfusion and subsequent mild ischemic
changes in the post mortem period. One animal showed organized lymphoid hyperplasia in the liver. None of the
animals demonstrated any significant pathological changes in the heart or kidney.

In Vivo Efficacy
A single post-training systemic injection or intracranial infusion of E2 or agonists of ERα or ERβ, including DPN,
enhances memory consolidation in the object recognition and object placement via rapid nonclassical (aka,
nongenomic) effects.(6,34,38−40,42,61) These compounds activate numerous cell signaling pathways in the dorsal
hippocampus within 5 min of dorsal hippocampal infusion, and pharmacological inhibition of this activation prevents
E2, DPN, and the ERα agonist PPT from enhancing memory.(6,34,58) The nonclassical nature of these effects have
been demonstrated in studies showing that they require interactions among ERα, ERβ, and metabotropic glutamate
receptors at the plasma membrane.(34) In the present study, in vivo behavioral assays measuring object placement or
object recognition (Figure 8a) showed efficacy for all three routes of administration: microinfusion into the dorsal
hippocampus, intraperitoneal injection, or oral gavage (Figure 8). Thus, ISP358-2 can enhance object recognition and
spatial memory consolidation in ovariectomized female mice. Intrahippocampal infusion of 100 pg and 1 ng of ISP3582 enhanced memory consolidation in the object recognition and object placement tasks as effectively as the ERβ
agonist DPN (Figure 8b,c). In systemic administration experiments, 0.5 mg/kg ISP358-2 most effectively enhanced
consolidation in both tasks when delivered intraperitoneally (Figure 8d,e), whereas 5 mg/kg ISP358-2 was most
effective via oral gavage (Figure 8f,g). These data are consistent with previous findings showing that intrahippocampal
or systemic administration of the ERβ agonists DPN or WAY200070 enhance hippocampal-dependent memory in
ovariectomized rats and mice in tasks including object recognition, object placement, and the radial arm
maze.(3,34,39−42) As such, ISP358-2 mimics the memory-enhancing effects of other ERβ agonists with different
chemical structures and could potentially be used to reduce memory dysfunction in numerous neuropsychiatric
conditions for which women are at increased risk, including AD, depression, and schizophrenia.(43) Moreover,
women are at greater risk of anxiety disorders than men,(43) and DPN decreases anxiety-related behaviors among
rodents tested in the open field and elevated plus maze tasks.(44,45) Thus, ISP358-2 has the potential to not only

facilitate memory consolidation but also to reduce anxiety. Although promising, numerous issues remain to be
addressed in future studies, including the extent to which the beneficial effects of ISP358-2 generalize to males, older
subjects, rodent models of AD and other disorders, and other forms of memory.
Finally, while it was observed that ISP358-2 is highly selective for ERβ over ERα in the more biologically relevant cellbased assay, it is not known if it has this same selectivity for ERβ in vivo. However, our preliminary studies have
shown a correlation between behavioral results and levels of ERβ in the brain, consistent with the effect being related
to ERβ agonist activity (Supporting Information, Figure S5). While the observed behavioral effects are consistent with
the predicted blood–brain barrier (BBB) penetration (Supporting Information, Figure S10) and subsequent activation
of ERβ, future studies will be directed toward determining the pharmacological mechanism of ISP358-2 in vivo,
including in vivo studies of isoform selectivity, effects on signaling cascades, and neural morphology changes in the
brain as well as pharmacokinetics and pharmacodynamics.

Conclusion
The results of the current study demonstrate that our lead compound, ISP358-2, is selective for ERβ and shows no
obvious signs of peripheral toxicity. Importantly, ISP358-2 also enhances multiple types of memory dependent on the
hippocampus, a brain region involved in numerous disorders including AD, depression, and
schizophrenia.(43,46) ISP358-2 is distinct from previously reported ERβ agonists in that it has higher selectivity for
ERβ over ERα and in that it more closely resembles that naturally occurring 17β-estradiol molecule (Figure 1d) as an
A–C estrogen. Our studies also demonstrated biological efficacy in behavioral assays that were performed via three
routes of administration: direct dorsal hippocampal infusion, intraperitoneal injection, and oral gavage, the latter two
of which illustrate brain penetrance of the effective doses (Figure 8). Overall, these findings suggest that the novel
ERβ agonist ISP358-2 could be a promising drug candidate for enhancing memory in a variety of disorders
characterized by memory dysfunction that occurs under low estrogen conditions, such as menopause.

Experimental Section
Compound Synthesis
All the chemicals were purchased from Sigma-Aldrich, Matrix Scientific, or Alfa Aesar and used as received. Reactions
with moisture- or air-sensitive reagents were conducted under an inert atmosphere of nitrogen in oven-dried
glassware with anhydrous solvents. Reactions were followed by TLC on precoated silica plates (60 Å, F254, EMD
Chemicals Inc.) and were visualized by UV lamp (UVGL-25, 254/365 nm). Flash column chromatography was
performed by using flash silica gel (32–63 μ). NMR spectra were recorded on Varian Unity Inova 400 MHz instrument.
CDCl3, acetone-d6, and CD3OD were purchased from Cambridge Isotope Laboratories. 1H NMR spectra were calibrated
to δ = 7.26 ppm for residual CHCl3, δ = 2.05 ppm for acetone-d6, and δ = 3.30 ppm for residual CD3OD-d3. 13C NMR
spectra were calibrated from the central peak at δ = 77.23 ppm for CDCl3, δ = 29.92 ppm for acetone-d6 and δ = 49.00
ppm for CD3OD. Purity of all compounds was >95%, determined with chromatography and NMR.
trans-4-(4-Hydroxycyclohexyl)phenol (2)

To a solution of 1 (0.200 g, 5.30 mmol) in anhydrous methanol (15 mL) at room temperature was added solid
NaBH4 (0.400 g, 10.6 mmol). The mixture was stirred for 3 h and then extracted with several times with ethyl acetate.
The combined extracts were concentrated to give 2 (0.181 g, 90%) as a colorless solid; mp 196–208 °C. 1H NMR (400
MHz, CD3OD) δ 7.00 and 6.67 (AA′XX′, JAX = 8.7 Hz, 4H), 3.61–3.53 (m, 1H), 2.38 (tt, J = 11.8, 3.4 Hz, 1H), 2.05–1.98 (m,
2H), 1.87–1.78 (m, 2H), 1.56–1.30 (m, 4H) ppm. 13C NMR (100 MHz, CD3OD) δ 156.6, 139.2, 128.7, 116.1, 71.4, 49.3,
44.3, 36.9, 34.2 ppm. HRMS m/z 191.1077 [calcd for C12H15O2– (M – H+) 191.1077].

4-(4-Hydroxy-4-methylcyclohexyl)phenol (3)

To a solution of 1 (0.100 g, 0.526 mmol) in dry ether (20 mL) at −78 °C under N2 was slowly added a solution of
methyllithium–lithium bromide complex (1.5 M in ether, 0.78 mL, 1.2 mmol). The mixture was stirred at −78 °C for 30
min, warmed to room temperature, and stirred for another 1 h. The mixture was cooled to 0 °C and quenched with
water. The mixture was extracted several times with ether and the combined extracts dried (Na2SO4) and
concentrated. The residue was purified by column chromatography (SiO2, hexanes–ethyl acetate = 4:1) to
give 3 (0.040 g, 37%) as a colorless solid; mp 126–131 °C. 1H NMR (400 MHz, CD3OD) δ 7.03 and 6.67 (AA′XX′, JAX = 8.3
Hz, 4H), 2.35 (tt, J = 12.4, 3.6 Hz, 1H), 1.87–1.69 (m, 4H), 1.61–1.44 (m, 4H) 1.21 (s, 3H). 13C NMR (100 MHz, CD3OD) δ
156.5, 140.0, 128.8, 116.1, 69.5, 44.5, 40.0, 31.9, 31.1 ppm. HRMS m/z 205.1234 [calcd for C13H17O2– (M – H+)
205.1234]. Anal. Calcd for C13H18O2: C, 75.69; H 8.79. Found: C, 75.33; H, 8.83.
4-(4-Hydroxyphenyl)cyclohexanone Oxime (4)

To a solution of 1 (0.050 g, 0.26 mmol) in ethanol (10 mL) were added Amberlyst (0.060 g) and hydroxylamine
hydrochloride (0.039 g, 0.560 mmol). The mixture was stirred at room temperature for 2 h and then filtered. The
filtrate was concentrated and extracted several times with ethyl acetate. The combined organic extracts were washed
with water, dried (MgSO4), and concentrated to give 4 as a colorless solid (0.037 g, 70%); mp 171–174 °C. 1H NMR
(400 MHz, CD3OD) δ 7.00 and 6.69 (AA′XX′, JAX = 8.2 Hz, 4H), 3.39 (broad d, J = 13.5 Hz, 1H), 2.67 (t, J = 12.8 Hz, 1H),
2.41 (broad d, J = 14.0 Hz, 1H), 2.20 (td, J = 14.6, 5.4 Hz, 1H), 1.93 (broad t, J = 15.8 Hz, 2H), 1.81 (td, J = 14.0, 5.2 Hz,
1H), 1.61–1.42 (m, 2H) ppm. 13C NMR (100 MHz, CD3OD) δ 160.8, 156.7, 138.3, 128.6, 116.2, 44.1, 35.8, 34.6, 32.8,
25.1 ppm. Anal. Calcd for C12H15NO2: C, 70.22; H 7.36; N, 6.83. Found: C, 69.93; H, 7.36; N, 6.63.
4-(4-t-Butyldimethylsilyloxyphenyl)cyclohexan-1-one (5)

To a solution of 1 (0.500 g, 2.62 mmol) in anhydrous CH2Cl2 (30 mL) at 0 °C under N2 was added imidazole (0.357 g,
5.24 mmol). After 30 min, t-butyldimethylsilyl chloride (0.594 g, 3.94 mmol) was added and the mixture was gradually
warmed to room temperature overnight. The resulting mixture was diluted with brine (25 mL) and extracted several
times with CH2Cl2. The combined organic extracts were dried (Na2SO4) and concentrated. The residue was purified by
column chromatography (SiO2, hexanes–ethyl acetate = 9:1) to give 5 (0.664, 83%) as a colorless solid; mp 39–42
°C. 1H NMR (400 MHz, CDCl3) δ 7.08 and 6.78 (AA′XX′, JAX = 8.4 Hz, 4H), 2.96 (t, J = 12.3 Hz, 1H), 2.56–2.40 (m, 4H),
2.25–2.14, (m, 2H), 1.97–1.82 (m, 2 H), 0.98 (s, 9H), 0.19 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3) δ 211.6, 154.3, 137.7,
127.7, 120.1, 42.2, 41.6, 34.6, 25.9, 18.4, −4.2 ppm.

t-Butyldimethyl(4-(4-methylenecyclohexyl)phenoxy)silane (6)

To a solution of methyltriphenylphosphonium bromide (0.836 g, 2.34 mmol) in dry THF (20 mL) at −10 °C under
N2 was slowly added a solution of n-butyllithium (1.6 M in hexane, 1.50 mL, 2.4 mmol). After 30 min, a solution
of 5 (0.502 g, 1.17 mmol) in dry THF (8 mL) was added dropwise. The reaction mixture was slowly warmed to room
temperature and stirred overnight. After this time, the mixture was diluted with water (20 mL), extracted several
times with ethyl acetate, and the combined extracts were dried (Na2SO4) and concentrated. Purification of the crude
residue by column chromatography (SiO2, hexanes–ethyl acetate = 9:1) gave 6 (1.678 g, 84%) as a colorless oil. 1H
NMR (400 MHz, CDCl3) δ 7.06 and 6.77 (AA′XX′, JAX = 8.3 Hz, 4H), 4.68 (s, 2H), 2.62 (tt, J= 12.1, 3.4 Hz, 1H), 2.42 (broad
d, J = 13.5 Hz, 2H), 2.18 (broad t, J = 13.2, 2H), 2.00–1.93 (m, 2H), 1.57–1.45 (m, 2H), 0.99 (s, 9H), 0.20 (s, 6H) ppm. 13C
NMR (100 MHz, CDCl3) δ 153.9, 149.2, 139.8, 127.8, 119.9, 107.4, 43.5, 35.9, 35.4, 25.9, 18.4, −4.2 ppm. Anal. Calcd
for C19H30O2Si: C, 75.43; H, 9.99. Found: C, 75.71; H, 10.02.
4-(4-Hydroxyphenyl)methylenecyclohexane (7)

To a solution of 6 (0.739 g, 0.244 mmol) in anhydrous THF (20 mL) was added a solution of TBAF (1 M in THF, 9.8 mL,
9.8 mmol). The mixture was heated at reflux for 5 h. After cooling, the solution was partitioned between ethyl acetate
and water, and the aqueous layer was extracted several times with ethyl acetate. The combined organic layers were
washed with brine, dried (Na2SO4), and concentrated. Purification of the residue by column chromatography (SiO2,
hexanes–ethyl acetate = 4:1) gave 7 (0.379 g, 83%) as a colorless solid; mp 82–84 °C. 1H NMR (400 MHz, CD3OD) δ 6.99
and 6.67 (AA′XX′, JAB = 8.5 Hz, 4H), 4.63 (t, J = 1.7 Hz, 2H), 2.57 (tt, J= 12.3, 4.3 Hz, 1H), 2.41–2.33 (m, 2H), 2.22–2.11
(m, 2H), 1.94–1.85 (m, 2H), 1.45 (qd, J = 12.3, 4.3 Hz, 2H). 13C NMR (100 MHz, CD3OD) δ 156.6, 150.3, 139.3, 128.8,
116.2, 107.8, 44.8, 37.3, 36.4 ppm. HRMS m/z 187.1128 [calcd for C13H15O– (M – H+) 187.1128]. Anal. Calcd for C13H16O2:
C, 82.93; H 8.57. Found: C, 82.71; H, 8.58.
4-(4-Methylcyclohexyl)phenol (8)

To a solution of 7 (0.150 g, 0.797 mmol) in methanol (10 mL) was added 10% Pd/C (85 mg, 10 mol %). The mixtures
was stirred under a balloon filled with H2, at room temperature, for 12 h. The reaction mixture was filtered through a
pad of Celite, dried (Na2SO4), and concentrated. The residue was purified by column chromatography (SiO2, hexanes–
ethyl acetate = 4:1) to give 8(0.121 g, 80%) as a colorless solid. This was determined to be a mixture of cis- and transstereoisomers by 1H NMR spectroscopy; mp 93–99 °C. 1H NMR (400 MHz, CD3OD) δ 7.05–6.96 (m, 2H), 6.70–6.64 (m,
2H), 2.48–2.28 (m, 1H), 1.83–1.34 (m, 8H), 1.13–1.04 (m, 1H), 1.03 (d, J = 7.2 Hz, 1H), 0.92 (d, J = 6.6 Hz, 2H). 13C NMR
(100 MHz, CD3OD) d 156.3, 140.0, 128.6, 116.0, 44.7, 36.9, 35.9, 33.7, 33.1, 30.1, 23.1 ppm.

2-Hydroxy-5-(4-methylenecyclohexyl)benzaldehyde (9)

To a solution of 7 (0.100 g, 0.531 mmol) in dry CH3CN (20 mL) were sequentially added MgCl2(0.076g, 0.797) and
triethylamine (0.28 mL, 2.0 mmol), followed by paraformaldehyde (0.108 g, 3.59 mmol). The mixture was heated at
reflux for 6 h. The mixture was cooled to room temperature and quenched with 10% HCl (10 mL) and extracted
several times with ethyl acetate. The combined extracts were washed with brine, dried (Na2SO4), and concentrated.
Purification of the residue by column chromatography (SiO2, hexanes–diethyl ether = 4:1) gave 9 (0.046 g, 40%) as a
colorless oil. 1H NMR (400 MHz, CD3OD) δ 9.96 (s, 1H), 7.50 (s, 1H), 7.39 (d, J = 8.5 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 4.65
(t, J = 1.7 Hz, 2H), 2.68 (tt, J = 12.0, 3.4 Hz, 1H), 2.44–2.34 (m, 2H), 2.24–2.13 (m, 2H), 1.97–1.89 (m, 2H), 1.49 (qd, J =
13.0, 4.0 Hz, 2H). 13C NMR (100 MHz, CD3OD) δ 197.5, 161.0, 149.8, 139.9, 137.0, 131.6, 122.5, 118.2, 108.2, 44.3,
36.9, 36.2 ppm. HRMS m/z 231.1027 [calcd for C14H15O3– (M – H+) 231.1027].
2-Hydroxy-5-(4-methylenecyclohexyl)benzaldehyde Oxime (10)

To a solution of 9 (0.050 g, 0.232 mmol) in pure ethanol (10 mL) were added sodium bicarbonate (0.024 g, 0.278
mmol) and hydroxylamine hydrochloride (0.025 g, 0.348 mmol). The reaction was heated at 80 °C for 5 h, and the
mixture was extracted several times with ethyl acetate. The combined organic extracts were dried (MgSO4) and
concentrated. Purification of the residue by column chromatography (SiO2, hexanes–ethyl acetate = 13:7)
gave 10 (0.037 g, 69%) as a colorless solid; mp 120–125 °C. 1H NMR (400 MHz, CD3OD) δ 8.20 (s, 1H), 7.09–7.06 (m,
1H), 7.05 (d, J = 2.4 Hz, 1.8H), 6.99 (d, J = 7.9 Hz, 0.2H), 6.78 (d, J = 8.1 Hz, 0.8H), 6.68 (d, J = 8.6 Hz, 0.2H), 4.63 (t, J =
1.6 Hz, 2H), 2.60 (tt, J = 12.2, 3.3 Hz, 1H), 2.42–2.33 (m, 2H), 2.22–2.10 (m, 2H), 1.94–1.85 (m, 2H), 1.46 (qd, J = 12.5,
4.0 Hz, 2H). 13C NMR (100 MHz, CD3OD) δ 156.6, 152.4, 150.1, 139.4, 130.2, 129.2, 128.7, 118.5, 117.2, 116.2, 108.0,
107.7, 44.5, 37.3, 37.1, 36.4, 36.3 ppm. HRMS m/z 230.1187 [calcd for C14H16NO3– (M – H+) 230.1186].
4-(4-((t-Butyldimethylsilyl)oxy)phenyl)-1-(hydroxymethyl)cyclohexan-1-ol (11)

To a solution of 6 (0.280 g, 0.926 mmol) and N-methylmorpholine-N-oxide (0.13 mL, 1.3 mmol) in acetone (6 mL) and
distilled water (0.3 mL) was added a solution of OsO4 in tert-butanol (2.5%, 90 μL). The mixture was stirred overnight,
and saturated aqueous NaHSO3 (10 mL) was added to quench the reaction. The mixture was diluted with ether and
washed several times with water. The organic layer was dried (MgSO4), concentrated, and the residue purified by
column chromatography (SiO2, hexanes–ethyl acetate = 1:4) to give 11 (0.267 g, 86%) as a colorless solid; mp 80–86

°C. 1H NMR (400 MHz, CDCl3) δ 7.04 and 6.75 (AA′XX′, JAX = 8.5 Hz, 4H), 3.69 (s, 2H), 2.52 (tt, J = 11.4, 3.6 Hz, 1H), 2.04–
1.72 (m, 4H, solvent peak overlap), 1.61–1.37 (m, 4H), 0.97 (s, 9H), 0.18 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 154.0,
138.9, 127.7, 120.0, 72.4, 66.2, 42.8, 35.4, 31.3, 25.9, 18.4, −4.2 ppm.
4-(4-Hydroxy-4-(hydroxymethyl)cyclohexyl)phenol (12)

To a solution of 11 (0.230 g, 0.683 mmol) in anhydrous THF (10 mL) was added a solution of TBAF (1 M in THF, 2.8 mL,
2.8 mmol). The mixture was heated at reflux for 6 h and cooled to room temperature. The solution was partitioned
between ethyl acetate and water. The combined organic layers were washed with brine, dried (Na2SO4), and
concentrated. Purification of the residue by column chromatography (SiO2, ethyl acetate–methanol = 9:1)
gave 12 (0.118 g, 78%) as a colorless solid; mp 182–188 °C. 1H NMR (400 MHz, CD3OD) δ 7.02 and 6.68 (AA′XX′, JAX =
8.5 Hz, 4H), 3.62 (s, 2H), 2.53–2.42 (m, 1H), 1.99–1.89 (m, 2H), 1.85–1.68 (m, 2H), 1.58–1.43 (m, 4H). 13C NMR (100
MHz, CD3OD) δ 156.6, 138.9, 128.8, 116.2, 73.1, 66.6, 44.3, 36.0, 32.6 ppm. Anal. Calcd for C13H18O3: C, 70.24; H, 8.16.
Found: C, 70.18; H, 7.78.
4-(4-t-Butyldimethylsilyloxyphenyl)cyclohexyl)methanol (13/14)

To a solution of 6 (0.821 g, 2.71 mmol) in THF (24 mL) at 0 °C under N2 was added a solution of borane–THF complex
(1 M in THF, 5.4 mL, 5.4 mmol). The reaction mixture was slowly warmed to room temperature and stirred for 20 h.
The mixture was then cooled to 0 °C, followed by sequential addition of ethanol (50 mL), hydrogen peroxide solution
(30% in water, 4.0 mL), and 1N NaOH solution (20 mL). The mixture was warmed to room temperature and stirred for
90 min. The reaction mixture was quenched with saturated sodium bicarbonate solution (10 mL), diluted with water
(20 mL), and extracted with several times with ethyl acetate. The combined organic extracts were washed with brine,
dried (Na2SO4), and concentrated. Purification of the residue by column chromatography (SiO2, hexanes–ethyl acetate
= 7:3) gave a colorless oil (0.572 g, 66%). This was determined to be a 2:1 mixture of cis-13 and trans-14 by 1H NMR
integration of the signals for the CH2OH groups at δ 3.69 and 3.50 ppm, respectively. 1H NMR (400 MHz, CDCl3) δ 7.06
and 6.76 (AA′XX′, JAX = 8.5 Hz, 4H), 3.69 (d, J = 7.4 Hz, 1.3H), 3.50 (d, J = 6.5 Hz, 0.7 H), 2.59–2.51 (m, 0.5H), 2.42 (tt, J =
12.1, 3.8 Hz, 0.5H), 1.96–1.84 (m, 2H), 1.80–1.37 (m, 7H), 0.98 (s, 9H), 0.19 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3) δ
153.7, 140.4, 140.0, 127.8, 119.9, 68.9, 64.6, 43.8, 42.6, 40.3, 36.2, 34.1, 30.0, 29.4, 27.0, 25.9, 18.4, −4.2 ppm. Use of
9-BBN instead of BH3–THF gave a 2:3 mixture of cis-13:trans-14 (74%).
4-(4-(Hydroxymethyl)cyclohexyl)phenol (15/16)

To a solution of 13/14 (0.594 g, 1.85 mmol, 2:1 mixture c:t) in dry THF (10 mL) was added a solution of TBAF (1 M in
THF, 7.5 mL, 7.5 mmol). The reaction mixture was heated to reflux at 70 °C overnight and cooled to room
temperature. The solution was partitioned between ethyl acetate and water. The organic layer was washed with
brine, dried (Na2SO4), and concentrated. The residue was purified by column chromatography (SiO2, hexanes–ethyl

acetate = 3:2) to give a colorless solid (0.280 g, 73%). This was determined to be a 2:1 mixture of cis-13 and trans14stereoisomers by 1H NMR integration of the signals for the CH2OH groups at δ 3.60 and 3.39 ppm, respectively; mp
118–122 °C. 1H NMR (400 MHz, CD3OD) δ 7.04–6.98 (m, 2H), 6.70–6.65 (m, 2H), 3.60 (d, J = 7.6 Hz, 1.5H), 3.39 (d, J =
6.6 Hz, 0.5H), 2.54–2.44 (m, 1H), 2.37 (tt, J = 12.1, 3.4 Hz, 1H), 1.93–1.70 (m, 3H), 1.61 (d, J = 6.3 Hz, 4H), 1.46–1.37
(m, 1H), 1.14–1.02 (m, 1H) ppm. 13C NMR (100 MHz, CD3OD) δ 156.2, 139.6, 128.7, 116.0, 68.0, 64.4, 45.2, 44.0, 41.4,
37.0, 35.4, 31.2, 30.5, 28.0 ppm.
1-(4-Hydroxyphenyl)-2-oxabicyclo[2.2.2]octane (17) and trans-(Hydroxymethyl)cyclohexyl)phenol (16)

To a solution of 15/16 (0.080 g, 0.388 mmol, 2:3 mixture of cis-15:trans-16) in anhydrous CH2Cl2(20 mL) at −10 °C was
slowly added, over a period of 30 min, a suspension of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.044 g, 0.194
mmol) in CH2Cl2 (4 mL). The green solution was stirred at 0 °C for 2 h and gradually warmed to room temperature and
stirred for another 3 h. The mixture was quenched by slow addition of saturated sodium bicarbonate solution at 0 °C.
After 10 min, the layers were separated and the aqueous layer was extracted several times with CH2Cl2. The combined
organic extracts were washed with brine, dried (Na2SO4), and concentrated. The residue was purified by column
chromatography (SiO2, hexanes–ethyl acetate = 3:2) to give 17(0.029 g, 37%) followed by 16 (0.038 g, 47%), both as
colorless solids. Purity of 16 was established by 1H NMR (Supporting Information, Figure S9).
17: mp 120–124 °C. 1H NMR (400 MHz, CD3OD) δ 7.18 and 6.64 (AA′XX′, JAX = 7.9 Hz, 4H), 4.04 (s, 2H), 2.01 (t, J = 7.8
Hz, 4H), 1.94–1.73 (m, 5H). 13C NMR (100 MHz, CD3OD) δ 157.3, 139.0, 127.2, 115.8, 73.2, 71.5, 34.7, 27.5, 26.1 ppm.
Anal. Calcd for C13H16O2: C, 76.44; H, 7.89. Found: C, 76.39; H, 7.97.
16: mp 115–120 °C. 1H NMR (400 MHz, CD3OD) δ 7.00 and 6.68 (AA′XX′, JAX = 8.7 Hz, 4H), 3.39 (d, J = 6.7 Hz, 2H), 2.36
(tt, J = 12.1, 3.0 Hz, 1H), 1.87 (broad t, J = 15.4, 4H), 1.55–1.36 (m, 3H), 1.14–1.02 (m, 2H). 13C NMR (100 MHz, CD3OD)
δ 156.5, 140.0, 128.7, 116.1, 68.9, 45.3, 41.5, 35.5, 31.3 ppm. Anal. Calcd for C13H18O2: C, 75.69; H, 8.79. Found: C,
75.66; H, 9.09.
4′-(Hydroxymethyl)-2′,3′,4′,5′-tetrahydro-[1,1′-biphenyl]-4-ol ((±)-19)

To a solution of 17 (0.103 g, 0.504 mmol) in dry CH3CN (25 mL) was added MgCl2 (0.072 g, 0.756 mmol) followed by
triethylamine (0.26 mL, 1.89 mmol). The mixture was heated at reflux for 8 h then cooled and quenched with 10% HCl
(15 mL). The mixture was extracted several times with ethyl acetate, and the combined extracts washed with brine,
dried (Na2SO4), and concentrated. Purification of the residue by column chromatography (SiO2, hexanes–ethyl acetate
= 13:7) gave 19 (0.080 g, 78%) as a colorless solid; mp 177–184 °C. 1H NMR (400 MHz, CD3OD) δ 7.20 and 6.69
(AA′XX′, JAX = 8.6 Hz, 4H), 5.97–5.92 (m, 1H), 3.48 (dd, J = 6.4, 2.6 Hz, 2H), 2.49–2.23 (m, 3H), 2.01–1.71 (m, 4H), 1.43–
1.31 (m, 1H). 13C NMR (100 MHz, CD3OD) δ 157.5, 137.7, 135.3, 127.2, 122.1, 116.0, 68.0, 37.5, 30.1, 28.2, 27.2 ppm.
HRMS m/z 203.1078 [calcd for C13H15O2–(M – H+) 203.1077].
4-(4-((t-Butyldiphenylsilyl)oxy)phenyl)cyclohexan-1-one (21)

To a solution of 1 (0.815 g, 4.28 mmol) in dry CH2Cl2 (30 mL) at 0 °C was added imidazole (0.583 g 8.57 mmol) followed
by dropwise addition of a solution of t-butyldiphenylsilyl chloride (1.60 mL, 5.57 mmol) in CH2Cl2 (9 mL). The reaction
mixture was slowly warmed to room temperature and stirred for 12 h. The mixture was diluted with water and

extracted several times with CH2Cl2. The combined extracts were washed with brine, dried (Na2SO4), and
concentrated. The residue was purified by column chromatography (SiO2, hexanes–ethyl acetate = 4:1) to
give 21 (1.70 g, 93%) as a colorless solid; mp 83–84 °C. 1H NMR (400 MHz, CDCl3) δ 7.74–7.70 (m, 4H), 7.45–7.34 (m,
6H), 6.96 and 6.71 (AA′BB′, JAB = 8.6 Hz, 4H), 2.90 (tt, J = 12.1, 3.3 Hz, 1H), 2.49–2.42 (m, 4H), 2.19–2.10 (m, 2H), 1.91–
1.77 (m, 2H), 1.09 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 211.6, 154.3, 137.3, 135.7, 133.2, 130.1, 127.9, 127.5, 119.8,
42.1, 41.6, 34.3, 26.7, 19.7 ppm.
Methyl 2-(4-(4-t-Butyldiphenylsilyloxyphenyl)cyclohexylidene)acetate ((±)-22)

To a solution of trimethyl phosphonoacetate (0.160 mL, 0.980 mmol) in dry THF (5 mL) at 0 °C was added NaH (40 mg,
55% in mineral oil, 0.980 mmol). After stirring for 45 min, a solution of 21(0.350 g, 0.816 mmol) in dry THF (5 mL) was
added and the mixture was warmed to room temperature and stirred for 8 h. The mixture was diluted with water and
extracted several times with ether. The combined extracts were dried (MgSO4) and concentrated. The residue was
purified by column chromatography (SiO2, hexanes–ethyl acetate = 9:1) to give 22 (0.376 g, 95%) as colorless gum. 1H
NMR (400 MHz, CDCl3) δ 7.74–7.68 (m, 4H), 7.44–7.32 (m, 6H), 6.91 and 6.69 (AA′XX′, JAX = 8.6 Hz, 4H), 5.65 (s, 1H),
3.96–3.88 (m, 1H), 3.69 (s, 3H), 2.66 (tt, J = 12.1, 3.4 Hz, 1H), 2.38–2.24 (m, 2H), 2.04–1.93 (m, 3H), 1.59–1.46 (m, 2H),
1.08 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 167.4, 162.7, 154.0, 138.6, 135.7, 133.3, 130.0, 127.9, 127.5, 119.6, 113.3,
51.10, 43.3, 37.9, 35.9, 35.1, 29.7, 26.7, 19.7 ppm.
4-[(4-Hydroxyphenyl)cyclohexylidene]acetic Acid Ethyl Ester ((±)-23)

To a stirred solution of 22 (60 mg, 0.12 mmol) in dry THF (1 mL) was added a solution of tetrabutylammonium fluoride
(0.247 mL, 1.0 M in THF, 0.247 mmol). The solution was stirred at room temperature after 1 h, and then the mixture
was diluted with water and extracted with ethyl acetate. The combined extracts were washed with brine, dried, and
concentrated. The residue was purified by preparative TLC (SiO2, hexanes–ethyl acetate = 9:1) to give 23 (20 mg, 64%)
as a colorless solid; mp 92–94 °C. 1H NMR (CDCl3, 300 MHz) δ 7.08 and 6.77 (AA′XX′, JAB = 8.4 Hz, 4H), 5.68 (s, 1H), 4.58
(s, 1H), 4.17 (q, J = 7.1 Hz, 2H), 4.00–3.90 (m, 1H), 2.80–2.68 (m, 1H), 2.45–1.97 (m, 6H), 1.30 (t, J = 7.3 Hz, 3H). 13C
NMR (CDCl3, 75 MHz) δ 167.0, 162.2, 154.0, 138.6, 128.1, 115.4, 113.9, 59.8, 43.4, 37.9, 36.0, 35.2, 29.7, 14.5 ppm.
HRMS m/z 259.1339 [calcd for C16H19O3– (M – H+) 259.1340].
4-(4′-Hydroxyphenyl)(2-hydroxyethylidene)cyclohexane ((±)-25)

To a solution of 22 (275 mg, 0.551 mmol) in dry CH2Cl2 (2 mL) under N2 at −40 °C was added a solution of
diisobutylaluminum hydride (1.0 M in CH2Cl2, 1.41 mL, 1.41 mmol). After 90 min, saturated aqueous potassium
sodium tartrate was added and reaction mixture warmed to room temperature. After 2 h, the layers were separated
and the aqueous layer was extracted several times with CH2Cl2. The combined organic layers were dried, filtered
through a pad of Celite, and concentrated to give 4-(4′-t-butyldiphenylsilyloxyphenyl)(2hydroxyethylidene)cyclohexane (254 mg, quantitative) as a colorless gum. This compound was used without further
purification. To a solution of the crude allylic alcohol (235 mg, 0.514 mmol) in dry THF (1 mL) under nitrogen was
added a solution of tetrabutylammonium fluoride in (1.0 M in THF, 1.03 mL, 1.03 mmol). The solution was stirred for
3 h and then diluted with water and the resultant mixture extracted several times with ethyl acetate. The combined
extracts were washed with brine, dried, and concentrated. The residue was purified by column chromatography (SiO2,

hexanes–ethyl acetate = 4:1) to give 25 (90 mg, 80%) as a colorless solid; mp 165–166 °C. 1H NMR (acetone-d6, 300
MHz) δ 8.10 (s, 1H), 7.04 and 6.74 (AA′XX′, JAX = 8.4 Hz, 4H), 5.36 (t, J = 6.6 Hz, 1H), 4.17–4.02 (m, 2H), 2.78–2.70 (m,
1H), 2.64 (tt, J = 3.3, 12.0 Hz, 1H), 2.35–2.10 (m, 2H), 1.98–1.80 (m, 4H), 1.54–1.37 (m, 2H). 13C NMR (acetone-d6, 75
MHz) δ 156.5, 141.1, 138.6, 128.5, 123.6, 116.0, 58.5, 44.6, 37.5, 37.0, 36.2, 29.2. Anal. Calcd for C14H18O2: C, 77.03; H
8.31. Found: C, 77.20; H, 8.28.
4-[4-(2-Hydroxyethyl)cyclohexyl]phenol (26) and 4-(4-Ethylcyclohexyl)phenol (27)

A solution of 25 (50 mg, 0.23 mmol) in methanol (15 mL) with a small pinch of 20% Pd/C was stirred under H2 (30 psi)
for 12 h. The reaction mixture was filtered through a pad of Celite and concentrated, and the residue was purified by
preparative TLC (SiO2, hexanes–ethyl acetate = 13:7) to give 27 (28 mg, 60%), followed by 26 (7 mg, 14%) both as
colorless solids.
27: mp 120–125 °C. 1H NMR (acetone-d6, 300 MHz) δ 8.02 (s, 1H), 7.08–7.01 (m, 2H), 6.77–6.71 (m, 2H), 3.65–3.56 and
3.43–3.37 (m, 3H total), 2.52–2.33 (m, 1H), 1.91–1.00 (m, 11H). 13C NMR (acetone-d6, 75 MHz) δ 156.4, 139.5, 128.6,
115.9, 61.1, 60.4, 44.6, 41.4, 35.5, 34.8, 34.5, 31.1, 30.3 ppm. HRMS m/z 219.139 [calcd for C14H19O2– (M – H+)
219.1390].
26: mp 80–81 °C. 1H NMR (CDCl3, 300 MHz) δ 7.08 and 6.76 (AA′XX′, JAX = 8.1 Hz, 4H), 4.55 (s, 1H), 2.54–2.35 (m, 1H),
1.92–1.82 (m, 2H), 1.70–1.50 (m, 3H), 1.45–1.00 (m, 6H), 0.91 (t, J = 7.2 Hz, 3H) ppm.

TR-FRET Assay
LanthaScreen TR-FRET ER Alpha and Beta Competitive Binding Assay kits from Thermo Fisher Scientific were used to
perform the TR-FRET assays. These included a terbium-labeled anti-GST antibody, a fluorescent small-molecule ER α
or β ligand as a “tracer”, and a human ER α or β ligand-binding domain (LBD) that is tagged with glutathione-Stransferase (GST) in a homogeneous mix-and-read assay format.
The TR-FRET assay employs a Tb-anti-GST antibody that binds to a GST tag, and a fluorescently labeled estrogen
(tracer) binds in the active site pocket. The TR-FRET signal obtained decreases when competitor compounds displace
the fluorescently labeled tracer. Assays were performed according to kit instructions. Briefly, 1:5 dilution series of
compounds were made with DMSO then diluted in assay buffer such that the highest concentration tested in the
assay was 50 μM and DMSO was 1%. Assays were set up in 384-well white, small volume plates (Corning 4512). The
assay was incubated for 1 h in the dark at room temperature, after which plates were spun at 1000 rpm in a tabletop
centrifuge equipped with a swing-out rotor (Eppendorf 5810, rotor A-4-64). TR-FRET signal was read on a SpectraMax
M5 (Molecular Devices) setup according to Thermo Fisher Scientific machine settings (excitation of 332 nm, emissions
518 and 488 nm with a 420 nm cutoff, 50 μs integration delay, 400 μs integration time, and 100 flashes per read). The
TR-FRET ratio was calculated using the SoftmaxPro software by dividing the emission at 518 nm (fluorescein) by the
emission at 488 nm (Terbium). Data were normalized to E2, which had an EC50 of 0.25 ± 0.06 nM in this assay. Data
analysis was done using Prism (GraphPad Software, Inc., La Jolla, CA), with fits typically constrained to go to zero at
high concentrations of competing ligand. Standard deviations are for the nonlinear least-squares fit of the data. When
replicate assays and fits were done, curves are shown (Figure 2 and Supporting Information, Figure S1) and fitted EC50s
summarized in Table 1) for curves that gave median EC50 values.

Nuclear Hormone Receptor Specificity Assay
Selectivity measurements were performed using the SelectScreen cell-based nuclear receptor profiling service from
ThermoFisher (Figure 3). Nuclear receptors (NRs) to be screened in the specificity assay were selected based on two
main criteria: (a) sequence and structural similarity to estrogen receptor and (b) availability of the assay. When
choosing between possible isoforms, we chose those that were more likely to be involved in CNS function. This is a
FRET-based assay that uses GeneBLAzer technology. It detects ligand binding to and activation of a nuclear hormone
receptor of interest (ligand binding domain; LBD) that is fused to a GAL4 DNA binding domain (DBD), which upon
activation induces expression of β-lactamase. The assay has a Z′ ≥ 0.5 in agonist mode. Compound stocks were in
DMSO and diluted for assay concentrations of 0.25, 2.5, and 25 μM. Data for estrogen receptors were normalized to

E2, which had an EC50 of 0.107 nM for ERα and 0.579 nM for ERβ. Data for other receptors were normalized to an
appropriate control, which are listed with EC50 values in Supporting Information, Table S1. Repeat assays for ERα and
ERβ agonist assays in a 10-point curve were also completed (Figure 3b). Data again were normalized to E2, which had
EC50 values of 0.151 and 0.568 nM for ERα and ERβ, respectively.

Coactivator Assay
The LanthaScreen TR-FRET assay from ThermoFisher was used (Figure 4a), similar to the assay described above
(Figure 3), except this LanthaScreen assay has a fluorescently labeled coactivator peptide present. The assay
measures recruitment of the labeled coactivator peptide to the ERα or ERβ LBD, induced by the binding of the ER
agonist being assayed. The coactivator peptide is PGC1a, derived from the PPARγ coactivator protein 1a, and
containing an LXXLL motif (sequence: EAEEPSLLKKLLLAPANTQ). Data were normalized to E2, which had an EC50 of 2.58
and 2.79 nM for ERα and ERβ, respectively.

Cell-Based Assays

ERα and ERβ cell-based assays for both agonist and antagonist activity measurements were performed using kits
provided by Indigo Biosciences (Figure 5). Assays relied on a luciferase reporter gene that was downstream from
either an ERα- or ERβ-responsive promoter and activated by an added agonist or had agonist activity blocked by an
added antagonist. ER-induced luciferase expression was quantified using chemiluminescence, measured using a
SpectraMax M5 plate reader. Stock solutions of ligands were prepared in DMSO and diluted to final concentrations
(typically low nM to μM), using the Compound Screening Medium provided in the kit, such that the DMSO
concentration in the assay was kept below the assay limit of 0.4%. Vehicle controls were included in both agonist and
antagonist assays. Assays were conducted according to kit instructions. Briefly, cells directly from the freezer were
diluted in Cell Recovery Media (provided) and warmed for 5 min at 37 °C. The cell suspension was divided in half.
Estradiol, E2, was added to one-half of the cells for antagonist assays, while the remaining cells without E2 were used
for the agonist assay. Cells were plated, and compounds to be screened were added. Plates were incubated in an
incubator at 37 °C with 5% CO2 for 22 h. Assays were typically performed in duplicate. Luminescence was measured
using a SpectraMax M5 plate reader, after removal of media and addition of the Luciferin Detection Reagent. Data
were normalized to E2, which had agonist activity EC50 of 0.31 ± 0.03 and 0.022 ± 0.005 nM for ERα and ERβ,
respectively. Data were fitted to the equation below using GraphPad Prism:

As described for the TR-FRET assay fitting, EC50 values and standard deviations are from the nonlinear least-squares fit
of the data, and when replicate assays and fits were done, median values were reported in Table 1.

In Vitro Druggability Assays: CYP450 Binding, hERG, and Nephelometry

The P450-Glo Screening System from Promega Corporation (Madison, WI) was used to measure CYP450 (cytochrome
P450) inhibition, as described in the kit instructions. Assays were run in 96-well white plates (Corning 3912), and
luminescence was measured on a SpectraMax M5 instrument (Figure 6). The luminescence signal is proportional to
the amount of luciferin product formed by the CYP reaction. Compounds were prepared in DMSO, then an eight-step
1:2 dilution series was made in DMSO. This was diluted in water such that the DMSO in the assay did not exceed
0.25% and the highest final concentration of compound was 62.5 μM. After adding the relevant cytochrome P450
enzyme, the plate was incubated at 37 °C for 10 min to allow components to come to temperature. Next, the NADPH
regeneration system was added to activate the reaction on a luminogenic P450-Glo substrate and incubated at 37 °C
for 10–30 min according to kit instructions for each CYP enzyme. The enzyme reaction was stopped by the addition of
Luciferin Detection Reagent, and luminescence of the plate was read in a Spectramax M5 (Molecular Devices) after a
20 min incubation at room temperature. Data were normalized to positive controls (α-naphthoflavone for CYP1A2,
sulfaphenazole for CYP2C9, quinidine for CYP2D6, and ketoconazole for CYP3A4). Data analysis was with Prism
software, as described above.

Nephelometry was performed to determine the relative propensity of compounds to aggregate in solution
(Supporting Information, Figure S3a) based on the light scattering properties of the molecular aggregates. Compound
aggregation in solution is important to measure in screening campaigns, as aggregation is a common source of
artifactual activity and it provides a measure of compound solubility. Compounds were tested for aggregation in clear
96-well plates (Greiner BioOne). Progesterone was used as a positive control for compound aggregation. Data were
collected using a BMG NEPHELOStar Plus, equipped with a 635 nm laser.
hERG assays were performed using the SelectScreen service from ThermoFisher (Supporting Information, Figure S3b).
The assay is a fluorescence polarization assay that measures displacement of a fluorescently tagged predictor tracer,
as described.(47)

MTT Assays

Human breast cancer cells (MCF-7) were provided by Dr. Manish Patankar (Department of Obstetrics and Gynecology,
University of Wisconsin—Madison). Cells were cultured in Eagle’s Minimum Essential Media (EMEM) supplemented
with 10% fetal bovine serum and 0.01 mg/mL human recombinant insulin in 5% CO2 at 37 °C. A seeding density of
7000 cells per well was chosen and applied to a 96-well plate. After 24 h, treatments of ISP358-2, DPN, or estradiol in
media containing 0.1% dimethyl sulfoxide (DMSO) were applied to the cells at varying concentrations (10, 1, 0.1, 0.01,
and 0.001 μM). Negative, positive, and untreated control cells received 100% DMSO, 0.01 μM estradiol in EMEM or
EMEM with 0.1% DMSO content, respectively. Treated cells were incubated for 24 h, after which an 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed by adding 20% MTT in EMEM
solution to each well and incubating for 4 h. Formazan crystal metabolites were dissolved using 100% DMSO, and
absorbance was read at OD 570 nm as well as a reference of 650 nm using a VMax kinetic microplate reader
(Molecular Devices, CA) running Softmax Pro version 6.1. Absorbances were converted to cell number using a
standard growth curve. Two-sample equal variance t-tests were conducted using Microsoft Excel to determine if cell
proliferation was significantly different from untreated controls or cells treated with 0.1 μM E2.

Docking

Three dimensional (3D) conformations were prepared for all ligands before docking (Figure 7). AutoDock Tools (ADT)
version 1.5.6 was used prepare the ligand files for subsequent AutoDock calculations and assign Gasteiger charges.
The ERα receptor for agonist (pdb 1ere)(36) and antagonist (pdb 1err)(48) conformations were prepared for docking
calculations, and the ERβ receptor for agonist (pdb 2jj3)(49) and antagonist (pdb 1l2j)(50) conformations were also
prepared for docking calculations. ADT was used to add hydrogen atoms and partial charges to each atom of the
protein. The grid box was centered on the cocrystallized ligand, drawn to a box to incorporate active site amino acids
(Arg394, Glu353, and His524 for ERα and Arg346, Glu305, and His475 for ERβ), and the estradiol ligand was
removed.(51) AutoDock Vina(52) was used for docking calculations, with default parameters, except that an energy
range of 4 and exhaustiveness of 8 were used.(47,53−56) As a control experiment, 17β-estradiol was docked into the
structure of ERα (pdb 1ere), after removing 17β-estradiol, and found to adopt the same binding mode as for the
originally bound 17β-estradiol (Supporting Information, Figure S4).

Assessment of Memory Consolidation
Subjects

C57BL/6 female mice (8–10 weeks of age) were purchased from Taconic Biosciences. Mice were singly housed in a 12
h light/dark cycle room, with food and water ad libitum. All procedures with live mice were performed between 9:00
am and 6:00 pm in a room with a light intensity of dimmer than 100 lx. All procedures were approved by the
University of Wisconsin—Milwaukee Institutional Animal Care and Use Committee and observed policies of the
National Institutes of Health Guide for the Care and Use of Laboratory Animals.

General Experimental Design

A series of three experiments were conducted in mice that were bilaterally ovariectomized to remove the primary
source of circulating estrogens. In each experiment, a negative control (dimethyl sulfoxide, DMSO), positive control
(2,3-bis(4-hydroxyphenyl)-propionitrile, DPN), and multiple doses of ISP358-2 were administered to separate groups
of mice via one of three routes of administration: direct bilateral dorsal hippocampal infusion, intraperitoneal
injection, or oral gavage. All drugs were administered acutely immediately after training in object recognition and

object locations tasks designed to test hippocampal-dependent object recognition and spatial memory consolidation,
respectively, as described below (Figure 8).

Surgery

Four days after arrival in the laboratory, mice were bilaterally ovariectomized as described previously.(34,57,58) Mice
slated to receive dorsal hippocampal infusion of ISP358-2 were also implanted with guide cannulae into the dorsal
hippocampus (DH) as described previously.(30−32)Mice were anesthetized with isoflurane gas (2% isoflurane in 100%
oxygen) and placed in a stereotaxic apparatus (Kopf Instruments). Immediately after ovariectomy, mice were
implanted with two guide cannulae (22 gauge; C232G, Plastics One) aimed at the dorsal hippocampus (−1.7 mm AP,
±1.5 mm ML, −2.3 mm DV). Dummy cannulae (C232DC, Plastics One) were placed inside the guide cannulae to
conserve patency of the guide cannulae. Dental cement (Darby Dental) was applied to anchor the guide cannulae to
the skull and also served to close the wound. Mice were allowed to recover for 6 days before behavioral testing.

Drugs and Infusions

Dorsal hippocampal (DH) infusions or intraperitoneal (IP) injections were conducted immediately post-training as
described previously.(34,57,58) During infusions, mice were gently restrained and drugs delivered using an infusion
cannula (C3131, 28 gauge, extending 0.8 mm beyond the 1.5 mm guide). The infusion cannula was connected to a 10
μL Hamilton syringe using PE20 polyethylene tubing. The infusion was controlled by a microinfusion pump (KDS
Legato 180, KD Scientific) at a rate of 0.5 μL/min. Each infusion was followed by a 1 min waiting period to prevent
diffusion back up the cannula track and allow the drug to diffuse through the tissue. The negative control (“vehicle”)
was 1% DMSO in 0.9% saline. As a positive control, the ERβ agonist 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN,
Tocris Bioscience) was dissolved in 1% DMSO in saline and infused at a dose of 10 pg/hemisphere.(30) DPN has a 70fold higher affinity for ERβ than ERα,(59) and bilateral infusion of 10 pg/hemisphere into the dorsal hippocampus
previously enhanced memory consolidation in the object recognition and object placement tasks in young adult
ovariectomized mice.(34) ISP358-2 was dissolved in 1% DMSO to a concentration of 2 ng/μL and then diluted to
administer doses of 1 ng/hemisphere, 100 pg/hemisphere, and 10 pg/hemisphere.
For intraperitoneal injections, ISP358-2 was dissolved in 10% DMSO in physiological saline and injected at doses of 0.5
or 5 mg/kg in a volume of 10 mL/kg. DPN was dissolved in 10% DMSO in saline and injected at a dose of 0.05 mg/kg in
volume of 10 mL/kg. This dose previously enhanced object recognition memory consolidation in young adult
ovariectomized mice.(31) Vehicle controls received 10 mL/kg of 10% DMSO in saline. For oral gavage, all drugs were
administered in a volume of 10 mL/kg at the same doses as intraperitoneal injections; 0.5 or 5 mg/kg ISP358-2 and
0.05 mg/kg DPN. Vehicle controls received 10% DMSO in saline. In the procedure, a bulb tipped gastric gavage needle
(24 GA, 25 mm) was used to deliver the drugs directly to the stomach.

Memory Testing

Object recognition and object placement were performed as described previously.(34,57,58)Object recognition and
object placement evaluated object recognition memory and spatial memory, respectively, and required intact dorsal
hippocampal function.(39,60−62) Mice were first handled (30 s/d) for 3 days to acclimate them to the experimenters.
On the second day of handling, a small Lego was placed in the home cage to habituate the mice to objects. This Lego
was removed from the cage just before training. After 3 days of handling, mice were habituated to an empty white
arena (width, 60 cm; length, 60 cm; height, 47 cm) by allowing them to explore freely for 5 min each day for 2 days.
On the training day, mice were habituated for 2 min in the arena and then removed to their home cage. Two identical
objects were then placed near the northwest and northeast corners of the arena. Mice were returned to the arena
and allowed to explore until they accumulated a total of 30 s of exploring the objects (or until a total of 20 min had
elapsed). Immediately after this training, mice were removed from the arena, infused, and then returned to their
home cage. Object placement memory was tested 24 h after training by moving one of the training objects to the
southeast or southwest corner of the box. Because mice inherently prefer novelty, mice that remember the location
of the training objects spend more time with the moved object than the unmoved object. Mice performing at chance
(15 s) spend an equal amount of time with each object and demonstrate no memory consolidation. Thus,
consolidation of memory for the training objects is demonstrated if mice spend significantly more time than chance
with the moved object. Object recognition training was conducted 2 weeks after object placement. The object
recognition task used the same apparatus and general procedure as object placement, but instead of changing the
object location, one familiar object was replaced with a new object during testing. Object recognition testing occurred

48 h after training. As with object placement, mice accumulated 30 s of exploring the novel and familiar objects.
Because mice are inherently drawn to novelty, more time than chance spent exploring the novel object indicated
memory for the familiar training object. To maintain novelty, different objects were used in the object placement and
object recognition tasks. Because vehicle-infused female mice do not remember the location of the training objects
24 h after training,(34) a 24 h delay was used to test the memory-enhancing effects of drugs in object placement.
Similarly, because vehicle-infused female mice do not remember the familiar object 48 h after training,(34) a 48 h
delay was used to test the memory-enhancing effects of drugs in object recognition. For both tasks, the time spent
exploring each object and elapsed time to accumulate 30 s of exploration were recorded using ANYmaze tracking
software (Stoelting).

Behavioral Data Analysis

One-sample t-tests and one-way analyses of variance (ANOVAs) were conducted using GraphPad Prism 6 (La Jolla,
CA). One-sample t-tests were used to determine whether mice spent significantly more time than chance (15 s)
investigating the novel or moved object, indicating whether each group of mice successfully formed a memory of the
identity and location of the training objects. To determine the extent to which DPN or ISP358-2 treatment influenced
memory consolidation relative to vehicle, between-group comparisons were conducted for each behavioral task using
one-way ANOVAs, followed by Fisher’s LSD post hoc tests. Significance was determined at p > 0.05.

Assessment of Potential Peripheral Pathology

To assess possible toxicity of ISP358-2 treatment to peripheral organs, ovariectomized mice received a single
intraperitoneal injection of vehicle or ISP358-2, and liver, kidney, and heart tissues were collected 24 h later. Similar
to behavioral testing, ISP358-2 was injected at doses of 0.5 or 5 mg/kg in a volume of 10 mL/kg and DPN was injected
at a dose of 0.05 mg/kg in a volume of 10 mL/kg. Vehicle controls received 10 mL/kg of 10% DMSO in saline
(Supporting Information, Figure S6a). Tissues were fixed in 10% formalin buffered solution for 24 h. Twenty
specimens were processed and analyzed. Each specimen contained three pieces of tissue. The tissues from each
animal was transferred to a labeled cassette and processed on an automated tissue processor following standard
procedures. The tissues were then embedded in paraffin wax. No specific orientation of the tissue was performed.
Four-micrometer sections were cut from each paraffin block and placed onto a slide. The slides were then stained
using hematoxylin and eosin (H&E) on an automated stainer (Supporting Information, Figure S6b). The slides were
then examined by a pathologist (ACM) who is board certified in anatomical pathology by the American Board of
Pathology. All specimens contained three tissue samples corresponding to liver, kidney, and heart. In some instances,
portions of adjacent tissues were also present. For example, several specimens had a gall bladder. One specimen had
a portion of spleen. Each organ was examined for specific pathological changes. Three major categories of change
were examined: (1) Structural changes to the organs. For liver, the central vein, portal triads, and hepatocytes were
examined. For kidneys, the glomeruli and tubules were examined. For heart, the myocytes and coronary vessels were
examined. (2) Evidence of inflammation was evaluated including hepatitis, glomerulonephritis, interstitial nephritis,
and myocarditis. (3) Evidence of ischemic changes was examined. See Table 1 for a summary of the findings.
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